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Context: Advanced glycation end-products (AGEs) are thought to be involved in the pathogenesis
of Alzheimer’s disease. AGEs are products resulting from nonenzymatic chemical reactions be-
tween reduced sugars and proteins, which accumulate during natural aging, and their accumu-
lation is accelerated in hyperglycemic conditions such as type 2 diabetes mellitus.
Objective: The objective of the study was to examine associations between AGEs and cognitive
functions.
Design, Setting, and Participants: This study was performed as part of the Maastricht Study, a popu-
lation-based cohort study in which, by design, 215 participants (28.1%) had type 2 diabetes mellitus.
Main Outcome Measures: We examined associations of skin autofluorescence (SAF) (n  764), an
overall estimate of skin AGEs, and specific plasma protein-bound AGEs (n  781) with performance
on tests for global cognitive functioning, information processing speed, verbal memory (imme-
diate and delayed word recall), and response inhibition.
Results: After adjustment for demographics, diabetes, smoking, alcohol, waist circumference, total
cholesterol/high-density lipoprotein cholesterol ratio, triglycerides, and lipid-lowering medication
use, higher SAF was significantly associated with worse delayed word recall (regression coefficient,
b  0.44; P  .04), and response inhibition (b  0.03; P  .04). After further adjustment for systolic
blood pressure, cardiovascular disease, estimated glomerular filtration rate, and depression, as-
sociations were attenuated (delayed word recall, b  0.38, P  .07; response inhibition, b  0.02,
P  .07). Higher pentosidine levels were associated with worse global cognitive functioning (b 
0.61; P  .04) after full adjustment, but other plasma AGEs were not. Associations did not differ
between individuals with and without diabetes.
Conclusion: We found inverse associations of SAF (a noninvasive marker for tissue AGEs) with cognitive
performance, which were attenuated after adjustment for vascular risk factors and depression. (J Clin
Endocrinol Metab 100: 951–960, 2015)
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N()-(carboxymethyl)lysine; eGFR, estimated GFR; GFR, glomerular filtration rate; HbA1c,
glycosylated hemoglobin A1c; HDL, high-density lipoprotein; IGM, impaired glucose me-
tabolism; IQR, interquartile range; NGT, normal glucose tolerance; SAF, skin
autofluorescence.
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Dementia is highly prevalent worldwide, and the num-ber of people with dementia is expected to increase
rapidly (1). The most common cause of dementia is
Alzheimer’s disease (AD), which is characterized by pro-
gressive decline in cognitive function, more specifically
memory loss. It is associated with the presence and the
accumulation of neurofibrillary tangles and amyloid
plaques in the brain (2). Although the etiology of dementia
has not been elucidated, the relationship between, on the
one hand, type 2 diabetes mellitus and other cardiovas-
cular risk factors including hypertension, obesity, and
smoking and, on the other hand, the development of
dementia and cognitive decline has become more evi-
dent (3, 4).
Advanced glycation end-products (AGEs), which are
products resulting from nonenzymatic chemical reactions
between reduced sugars and proteins (5), are thought to be
involved in the pathogenesis of AD (6). AGEs accumulate
during natural aging, and their accumulation is acceler-
ated in hyperglycemic conditions such as type 2 diabetes
(5, 7). Long-lived proteins, including -amyloid (A),
have been found to be modified by AGEs, and a recent
study has shown that the formation of AGE-modified A
exacerbates the toxicity of A (8). AGEs are present in
both neurofibrillary tangles and senile plaques of patients
with AD (9), and the receptor for AGE appears to be in-
volved in the transport of amyloid peptides through the
blood–brain barrier (10). In addition, AD patients with
type 2 diabetes seem to have more severe AD pathology
and higher AGE levels in the brain compared with those
with AD alone (9).
AGEs can be measured in plasma (circulating AGEs) or
estimated in tissue using a relatively simple noninvasive
measurement of skin autofluorescence (SAF), a method
based on the fluorescent properties of some AGEs (11).
SAF has been suggested to be a simple alternative to in-
vasive measurement of AGE accumulation and has been
shown to be correlated with fluorescent (pentosidine) and
even nonfluorescent plasma AGEs (N()-(carboxymethyl)-
lysine [CML] and N()-(carboxyethyl)lysine [CEL]) in bi-
opsy-derived skin tissue (11). In addition, SAF has recently
been shown to be associated with lower gray matter
volume (12), and it may therefore be hypothesized that
SAF indicates AGE accumulation in other tissue, like the
brain, as well. Furthermore, SAF may reflect AGE ac-
cumulation more accurately than plasma proteins be-
cause intracellular glycation is thought to be the major
local source of AGEs and not all AGEs may end up in the
circulation (13, 14).
Although there is evidence that AGEs might be as-
sociated with dementia and cognitive decline, research
on the relationship between AGEs and cognitive function
is scarce. Yaffe et al (15) have shown that the AGE pen-
tosidine, measured in its free form in urine, was associated
with a greater 9-year cognitive decline in older people in-
dependent of diabetes status. Furthermore, Chen et al (16)
showed that higher levels of serum AGEs were cross-sec-
tionally associated with mild cognitive impairment in
diabetes patients. No study to date has investigated the
relationship between SAF and cognitive performance
on multiple cognitive domains. One recent study has
shown a cross-sectional association between higher SAF
and a higher likelihood of cognitive impairment, but it
did not examine associations with separate cognitive
functions (12).
Examination of the association between AGEs and cog-
nitive function might provide a marker for cognitive im-
pairment and might increase our knowledge about the
etiology of cognitive decline and dementia. Therefore, the
aim of our study was to examine the associations of SAF
and plasma AGEs with performance on a range of cogni-
tive tests in participants from the Maastricht Study, a
population-based cohort study. Next, we investigated
whether or not these associations were different in par-
ticipants with and without type 2 diabetes.
Subjects and Methods
Study population
In this study, we used data from the Maastricht Study, an
observational, prospective, population-based cohort study. The
rationale and methodology have been described previously (17).
In brief, the study focuses on the etiology, pathophysiology, com-
plications, and comorbidities of type 2 diabetes mellitus and is
characterized by an extensive phenotyping approach. Eligible for
participation were all individuals between 40 and 75 years of age
living in the southern part of The Netherlands. Participants were
recruited through mass media campaigns and from the municipal
registries and the regional Diabetes Patient Registry via mailings.
Recruitment was stratified according to known type 2 diabetes
status for reasons of efficiency. The present report includes cross-
sectional data from the first 866 participants who completed the
baseline survey between November 2010 and March 2012. The
examinations of each participant were performed within a time
window of 3 months. The study has been approved by the in-
stitutional medical ethical committee (NL31329.068.10) and
the Netherlands Health Council under the Dutch “Law for Pop-
ulation Studies” (Permit 131088–105234-PG). All participants
gave written informed consent.
Skin autofluorescence
All participants were asked to refrain from smoking and caf-
feine at least 3 hours before the measurements. A light meal
(breakfast and/or lunch), low in fat content, was allowed. SAF
was measured with the AGE Reader (DiagnOptics Technologies
BV). The AGE Reader is a desktop device that uses the charac-
teristic fluorescent properties of certain AGEs to estimate the
level of AGE accumulation in the skin. Technical details of this
952 Spauwen et al Advanced Glycation End-products and Cognition J Clin Endocrinol Metab, March 2015, 100(3):951–960
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noninvasive method have been described more extensively else-
where (11). In short, the AGE Reader illuminates a skin surface
of 4 cm2 guarded against surrounding light, with an excitation
wavelength range of 300–420 nm and a peak excitation of 370
nm. SAF was calculated as the ratio between the emission light
from the skin in the wavelength range of 420–600 nm (fluores-
cence) and excitation light that is reflected by the skin (300–420
nm), multiplied by 100 and expressed in arbitrary units (AU).
Participants were asked not to use any sunscreen or self-brown-
ing creams on their lower arms within 2 days before the mea-
surement. SAF was measured at room temperature in a semi-
dark environment while participants were at rest in a seated
position. The forearm of a participant was positioned on top of
the device, as described by the manufacturer. The mean of three
consecutive measurements was used in the analyses. Reproduc-
ibility was assessed in 14 individuals without diabetes (six males;
age, 32.2  7.1 y). The intraclass correlation coefficient of three
intraindividual consecutive SAF measurements was 0.83 (95%
confidence interval [CI], 0.65–0.94). SAF was calculated off-line
by automated analysis using AGE Reader software, version 2.3,
and was observer-independent. There were no significant differ-
ences between fasting and nonfasting measurements (mean dif-
ference  0.01 AU; P  .73). Reproducibility in individuals with
type 2 diabetes has been evaluated previously (11) with an overall
Altman error percentage of 5.03% for measurements taken over
a single day. Skin pigmentation is known to influence the
measurement of SAF (18). Therefore, in participants with
dark-colored skin with a reflectance of 6 –10%, a validated
reflectance-dependent correction was made by the software
(18). Measurements in participants with dark-colored skin and
a mean reflectance below 6% are considered unreliable and are
therefore not used to calculate SAF by the software. Therefore,
these participants were automatically excluded. Additionally, a
single SAF value above 10 AU was considered as unreliable; these
individual measurements (n  3) were manually excluded, and
the mean of the remaining two measurements was used in
analyses.
Analysis of protein-bound AGEs and lysine in
plasma
Plasma AGEs were measured in EDTA samples obtained
from fasting venous blood, which were stored at 80°C until
analysis. Protein-bound pentosidine was quantified using HPLC
with fluorescence detection, as described in detail elsewhere (19).
Intra- and interassay coefficients of variation for pentosidine, as
analyzed in this study, were 6.5 and 7.8%, respectively. Protein-
bound CML, CEL, and lysine were quantified using UPLC
MS/MS (ultraperformance) liquid chromatography-tandem MS
(14). Intra- and interassay coefficients of variation were 4.5 and
6.7% for CML, 6.2 and 10.3% for CEL, and 5.0 and 5.3% for
lysine. Concentrations of protein-bound pentosidine, CML, and
CEL were adjusted for levels of lysine and expressed as nano-
moles per millimole lysine.
Assessment of cognitive function
A concise battery (30 min) of cognitive tests was used to assess
cognitive functioning (17). An a priori selection of these cogni-
tive tests was used in the current study. Since diabetes is strongly
linked to AGE accumulation, we have chosen tests that each
represent cognitive domains (i.e. information processing speed,
verbal memory, and executive functions) which are often used
and have been shown to be most sensitive to effects of diabetes
(20). Global cognitive functioning was measured by the Mini-
Mental State Examination (MMSE) (score range, 0–30) (21).
Verbal memory was assessed with the Visual Verbal Word
Learning Test (22). In this test, 15 words are presented in five
subsequent trials, followed by a recall phase immediately after
each trial (immediate recall) (score range, 0–75) and a delayed
recall phase 20 minutes thereafter (delayed recall) (score range,
0–15). Response inhibition was measured with the Stroop Color
Word Test (23). The variable of interest was the interference
measure expressed in seconds. The Letter-Digit Substitution Test
(24) was used to measure information processing speed. Partic-
ipants were instructed to match digits to letters as quickly as
possible within 90 seconds.
Covariates
History of cardiovascular disease, diabetes duration, smok-
ing status (never, former, current), and alcohol consumption
were assessed by questionnaire (17). Participants were regarded
as having a history of cardiovascular disease if they reported to
have had a myocardial infarction, and/or cerebrovascular in-
farction or hemorrhage, and/or percutaneous artery angioplasty
of/or vascular surgery on the coronary, abdominal, peripheral,
or carotid arteries. Alcohol consumption was classified into three
categories: nonconsumers, low consumers ( seven glasses per
week for females and  14 glasses per week for males), and high
consumers ( seven glasses per week for females and  14
glasses per week for males). Use of lipid-lowering, antihyperten-
sive, and glucose-lowering medication was assessed during a
medication interview where generic name, dose, and frequency
were registered (17). Waist circumference, glycosylated hemo-
globin A1c (HbA1c), glucose levels, total and high-density lipo-
protein (HDL) cholesterol, creatinine, and triglycerides were de-
termined as described elsewhere (17). Estimated glomerular
filtration rate (eGFR) was estimated according to the CKD-EPI
(Chronic Kidney Disease Epidemiology Collaboration) equation
(25). Office blood pressure was determined three times on the
right arm after a 10-minute rest period using a noninvasive blood
pressure monitor (Omron 705IT, Omron, Japan) (17).
To determine glucose metabolism, all participants (except
those who use insulin) underwent a standardized seven-point
oral glucose tolerance test after an overnight fast as previously
described (17). Glucose metabolism was defined according to the
World Health Organization 2006 criteria as normal glucose tol-
erance (NGT), impaired fasting glucose, impaired glucose tol-
erance, and type 2 diabetes (26). Additionally, individuals with-
out type 1 diabetes and on diabetes medication were considered
as having type 2 diabetes (17). For this study, we defined having
either impaired fasting glucose or impaired glucose tolerance as
impaired glucose metabolism (IGM).
Level of education was assessed during the cognitive assess-
ment and was classified into eight categories commonly used in
The Netherlands (27): 1) no education; 2) primary education; 3)
lower vocational education; 4) intermediate general secondary
education; 5) intermediate vocational education; 6) higher gen-
eral secondary education; 7) higher vocational education; and 8)
university. For this study, three groups were created for educa-
tional level: low (levels 1–3), intermediate (levels 4–6), and high
(levels 7 and 8). Depression was assessed by the Mini Interna-
tional Neuropsychiatric Interview (17,28).
doi: 10.1210/jc.2014-2754 jcem.endojournals.org 953
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Statistical analysis
Analyses were conducted using the SPSS software, version 20
for Mac OSX (SPSS Inc). Differences between tertiles of SAF
were tested using ANOVA for continuous variables and 2 tests
for categorical variables. Multiple linear regression analysis was
used to estimate the association of SAF and of plasma AGEs with
cognitive performance, adjusted for different sets of covariates in
separate models. In model 1, we adjusted for age, which is a
known predictor of AGE accumulation and cognitive perfor-
mance and is therefore considered as an important potential con-
founder. In model 2, we added other potential important con-
founders: sex, educational level, and diabetes (yes/no). In model
3, we additionally adjusted for cardiovascular risk factors that
have been previously associated with higher AGE accumulation
and with cognitive performance, and therefore may be potential
confounders (ie, smoking, alcohol, waist circumference, total
cholesterol/HDL cholesterol ratio, triglycerides, and lipid-low-
ering medication use). Finally, in model 4, we adjusted for
variables that could be potential mediators of the associations
between AGEs and cognition, because they may be caused by
higher AGE accumulation and may cause cognitive impairment
(ie, systolic blood pressure, cardiovascular disease, depression,
and eGFR). Interaction effects were tested to examine whether
the association of SAF and plasma AGEs with cognitive perfor-
mance differed between participants with and without diabetes.
Pentosidine levels and response inhibition scores were log-trans-
formed before regression analysis, because they were positively




Four individuals with type 1 diabetes and four partic-
ipants who did not undergo cognitive assessment were
excluded. Of the remaining 858 participants, we addition-
ally excluded individuals with missing data on the inde-
pendent variables SAF (n  31) or plasma AGEs (n  19),
or on potential confounders (n  63). This resulted in 764
individuals available for complete case analyses with SAF
and 781 individuals for complete case analyses with
plasma AGEs. Participants excluded due to missing values
were more likely to have diabetes and use insulin, and they
had higher levels of HbA1c and SAF and lower scores for
cognitive performance (global cognitive functioning, in-
formation processing speed, immediate word recall, and
response inhibition) (P  .05). There were no differences
in other characteristics (data not shown).
Characteristics of the 764 participants included for
analyses with SAF are shown in Table 1, stratified accord-
ing to tertiles of SAF. Of these, 215 participants (28.1%)
had type 2 diabetes, of whom 35 (16.3%) were newly
diagnosed at study entry. Median diabetes duration was
7.0 years (interquartile range [IQR]  3.0–11.0), and
mean HbA1c level was 6.9% (SD  0.8). Of the 549
participants without diabetes, 126 (16.5% of the total
sample) had IGM.
Mean scores for cognitive tests in the total sample were
28.9 (SD  1.2) for global cognitive functioning, 48.8
digits (SD  9.3) for information processing speed, 45.4
words (SD  9.7) for immediate word recall, and 9.5
words (SD  2.9) for delayed word recall. The median
score for response inhibition was 41.7 seconds (IQR 
31.9–55.9). Participants with type 2 diabetes had signif-
icantly lower scores on all cognitive measures compared
with those with NGT (P  .001) after adjustment for age,
whereas participants with IGM did not perform signifi-
cantly worse on any cognitive test compared with those
with NGT (P  .10 for all cognitive measures). We there-
fore combined participants with NGT with those with
IGM for the interaction analyses.
Tertiles of SAF were significantly associated with age,
educational level, glucose metabolism status, smoking sta-
tus, alcohol consumption, waist circumference, systolic
blood pressure, history of cardiovascular disease, HbA1c
level, antihypertensive medication use, lipid-lowering
medication use, glucose-lowering medication use, eGFR,
pentosidine level, and cognitive functions (Table 1).
SAF and cognitive performance
In unadjusted analyses, a higher SAF level was signifi-
cantly associated with worse performance on all cognitive
measures (regression coefficient b  0.44, P  .001,
for global cognitive functioning; b  4.69, P  .001, for
information processing speed; b  5.28, P  .001, for
immediate word recall; b  1.51, P  .001, for delayed
word recall; b  0.11, P  .001, for response inhibition).
After adjustment for age (Table 2, model 1), SAF was still
significantly associated with all cognitive measures. After
further adjustment for sex, educational level, and diabetes
(Table 2, model 2), SAF was still significantly associated
with immediate and delayed word recall and with re-
sponse inhibition, but not with global cognitive function-
ing and information processing speed. After further ad-
justment for smoking status, alcohol consumption, waist
circumference, total cholesterol/HDL cholesterol ratio,
triglycerides, and lipid-lowering medication use (model
3), the association of SAF with immediate word recall was
attenuated and became nonsignificant. Associations with
delayed word recall and response inhibition were attenu-
ated but remained statistically significant. Associations of
SAF with delayed word recall and response inhibition
were attenuated and became nonsignificant after further
adjustment for systolic blood pressure, cardiovascular dis-
ease, eGFR, and depression (Table 2, model 4). In a post
hoc analysis, we additionally adjusted the associations for
antihypertensive medication (yes/no) use and glucose-
954 Spauwen et al Advanced Glycation End-products and Cognition J Clin Endocrinol Metab, March 2015, 100(3):951–960
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Table 1. Characteristics of the Study Group (n  764), Stratified by Tertiles of SAF
Characteristic Low Middle High
P
Value
n 254 255 255
SAF, AU, mean (SD) 2.17 (0.20) 2.65 (0.12) 3.27 (0.38)
Age, y, mean (SD) 54.9 (8.7) 60.2 (7.3) 63.8 (6.9) .001
Sex, male, n (%) 129 (50.8) 138 (54.1) 154 (60.4) .09
Educational level, low/
middle/high, n (%)




175/41/38 (68.9/16.1/15.0) 153/38/64 (60.0/14.9/25.1) 95/47/113 (37.3/18.4/44.3) .001
Smoking status, never/
former/current, n (%)
97/133/24 (38.2/52.4/9.4) 80/135/40 (31.4/52.9/15.7) 62/139/54 (24.3/54.5/21.2) .001
Alcohol consumption,
none/low/high, n (%)
39/141/74 (15.4/55.5/29.1) 34/126/95 (13.4/49.4/37.3) 57/136/62 (22.4/53.3/24.3) .01
Waist circumference,
cm, mean (SD)
95.2 (12.1) 96.0 (3.0) 100.0 (15.1) .001
Systolic blood pressure,
mm Hg, mean (SD)
134.1 (16.9) 137.4 (19.2) 139.6 (20.1) .01
Antihypertensive
medication, n (%)
68 (26.8) 95 (37.4) 140 (55.1) .001
Lipid-lowering
medication, n (%)




229/22/3 (90.2/8.7/1.2) 207/42/6 (81.2/16.5/2.4) 160/66/29 (62.7/25.9/11.4) .001
Cardiovascular disease,
n (%)
31 (12.2) 36 (14.1) 70 (27.5) .001
HbA1c, %, mean (SD) 5.8 (0.5) 5.9 (0.7) 6.3 (0.9) .001
Triglycerides, mmol/L,
median (IQR)
1.20 (0.82–1.73) 1.24 (0.85–1.76) 1.23 (0.88–1.88) .59*
Total cholesterol/HDL
cholesterol, mean (SD)
4.24 (1.26) 4.24 (1.24) 4.18 (1.27) .84
eGFR, mL/min/1.73 m2,
mean (SD)
89.1 (13.84) 85.83 (13.27) 79.86 (14.15) .001
Depression, n (%) 8 (3.1) 9 (3.5) 14 (5.5) .36
Pentosidine, nmol/mmol
LYS, median (IQR)
0.45 (0.37–0.53) 0.47 (0.38–0.55) 0.50 (0.40–0.60) .001*
CML, nmol/mmol LYS,
mean (SD)
74.8 (14.2) 74.6 (14.3) 73.8 (15.9) .67
CEL, nmol/mmol LYS,
mean (SD)




29.1 (1.2) 29.0 (1.2) 28.7 (1.3) .001
Information processing
speed,b mean (SD)
51.5 (9.3) 48.7 (8.7) 46.1 (9.2) .001
Immediate word recall,b
mean (SD)
48.0 (9.3) 46.4 (9.1) 41.8 (9.7) .001
Delayed word recall,b
mean (SD)a
10.3 (2.8) 9.7 (2.8) 8.5 (2.9) .001
Response inhibition,c
median (IQR)
37.8 (29.0–48.5) 41.1 (33.0–54.1) 48.1 (35.5–63.5) .001*
Abbreviations: LYS, lysine; T2DM, type 2 diabetes mellitus.
a Two participants in this group used glucagon-like peptide-1 receptor agonists in addition to oral glucose-lowering medication
b Higher scores indicate better performance.
c Lower scores indicate better performance.
* P values were derived from ANOVA with log-transformed outcomes.
doi: 10.1210/jc.2014-2754 jcem.endojournals.org 955
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lowering medication use (yes/no). The association with
delayed recall increased somewhat (b  0.41; P  .05),
whereas the association with response inhibition was
somewhat attenuated (b  0.02; P  .10). Other associ-
ations remained virtually unchanged (b  0.10, P  .32,
for global cognitive functioning; b  0.04, P  .96, for
speed; b  1.08, P  .12, for immediate word recall).
Interactions between SAF and diabetes on cognitive
measures were not significant (model 4, regression coef-
ficient b for interaction  0.31, P  .09, for global
cognitive functioning; b  0.09, P  .95, for speed; b 
0.41, P  .75, for immediate word recall; b  0.12, P 
.77, for delayed word recall; b  0.02, P  .35, for re-
sponse inhibition).
Plasma AGEs and cognitive performance
In unadjusted analyses, higher pentosidine levels were
significantly associated with worse immediate and de-
layed word recall and response inhibition (b  4.67, P 
.04, for immediate word recall; b  1.73, P  .01, for
delayed word recall; b  0.09, P  .04, for response in-
hibition). In adjusted models (Table 3), these associations
became nonsignificant, whereas the association between
pentosidine and global cognitive functioning became
stronger and significant (Table 3, model 4). After addi-
tional adjustment for antihypertensive and glucose-low-
ering medication use, these results were largely unchanged
(for global cognitive functioning, b  0.63, P  .03; for
speed, b  1.46, P  .47; for immediate word recall, b 
3.61,P .08; fordelayedword recall, b1.11,P .08;
for response inhibition, b  0.01, P  .72). Interactions
between pentosidine and diabetes on cognitive measures
werenot significant (model4,b for interaction 0.09,P
.87, for global cognitive functioning; b  3.30, P  .38,
for information processing speed; b  2.77, P  .47, for
immediate word recall; b  0.23, P  .85, for delayed
word recall; b  0.07, P  .38, for response inhibition).
Plasma CML and CEL were not significantly associated
with any cognitive measures after adjustment for con-
founders (Supplemental Tables 1 and 2, respectively). We
found no significant interactions between CML and dia-
Table 2. Adjusted Association Between SAF and Cognitive Performance
b (Regression
Coefficient) 95% CI P Value
Global cognitive functioninga
Model 1 0.25c 0.43 to 0.06 .01
Model 2 0.10 0.28 to 0.08 .29
Model 3 0.08 0.26 to 0.11 .42
Model 4 0.08 0.27 to 0.11 .41
Information processing speeda
Model 1 1.73 3.03 to 0.42 .01
Model 2 0.42 1.68 to 0.84 .52
Model 3 0.13 1.42 to 1.17 .84
Model 4 0.07 1.24 to 1.38 .91
Immediate word recalla
Model 1 2.58 3.96 to 1.20 .001
Model 2 1.39 2.68 to 0.10 .03
Model 3 1.15 2.46 to 0.17 .09
Model 4 0.97 2.30 to 0.36 .15
Delayed word recalla
Model 1 0.74 1.16 to 0.32 .001
Model 2 0.48 0.88 to 0.08 .02
Model 3 0.44 0.85 to 0.03 .04
Model 4 0.38 0.79 to 0.04 .07
Response inhibitionb
Model 1 0.05 0.03 to 0.08 .001
Model 2 0.03 0.00 to 0.05 .03
Model 3 0.03 0.00 to 0.05 .04
Model 4 0.02 0.00 to 0.05 .07
Model 1: Adjustment for age. Model 2: Model 1  adjustments for sex, diabetes, and educational level. Model 3: Model 2  adjustments for
smoking, alcohol consumption, waist circumference, total cholesterol/HDL cholesterol ratio, triglycerides, and lipid-lowering medication use. Model
4: Model 3  adjustments for systolic blood pressure, cardiovascular disease, depression, and eGFR.
a Higher scores indicate better performance (MMSE score for global cognitive functioning, number of digits for information processing speed,
number of words for total and delayed word recall).
b Lower scores indicate better performance. Scores for response inhibition (seconds) are log-transformed.
c A regression coefficient of 0.25 indicates that one unit increase in SAF level is associated with a decrease of 0.25 points on a test for global
cognitive functioning.
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betes on any of the cognitive measures (data not shown).
There was a significant interaction between CEL and di-
abetes on global cognitive functioning (b for interaction 
0.03; P  .003), but not on the other cognitive measures.
Stratified analyses showed that CEL was only associated
with global cognitive functioning in participants without
diabetes (b  0.01; P  .003), but not in participants
with diabetes (b  0.01; P  .13).
Sensitivity analysis
Z-scores for SAF and pentosidine were calculated for
each individual as their value for AGE level minus the
mean and divided by the SD of the study sample. In a
sensitivity analysis, we excluded participants with AGE
Z-scores higher than 3 or lower than 3 to examine
whether our results would change. Six participants had a
Z-score higher than 3. When these six participants were
excluded from analyses, the associations of SAF with im-
mediate word recall (model 4, b  0.99; P  .17) and
delayed word recall did not change (model 4, b  0.41;
P  .07), whereas the association of SAF with response
inhibition (b  0.02; P  .26) was attenuated. Other as-
sociations remained nonsignificant. For analyses with
pentosidine, we excluded 16 participants with Z-scores
larger than 3. The association of pentosidine with global
cognitive functioning (model 4, b  0.52; P  .15) was
attenuated and became nonsignificant. Other associations
remained nonsignificant.
Discussion
This is the first study to examine the association of SAF, as
an estimate of tissue AGE accumulation, and plasma
AGEs with multiple cognitive functions. Our results indi-
cate that SAF is inversely associated with memory, al-
though cardiovascular risk factors seem to be involved in
the association. In addition, we found associations be-
tween SAF and response inhibition and between pentosi-
dine and global cognitive functioning, which should be
interpreted with caution because these associations were
attenuated after excluding some influential cases. There-
Table 3. Adjusted Association Between Plasma Pentosidine and Cognitive Performance
b (Regression
Coefficient) 95% CI P Value
Global cognitive functioninga
Model 1 0.14c 0.70 to 0.42 .62
Model 2 0.46 1.00 to 0.07 .09
Model 3 0.51 1.05 to 0.04 .07
Model 4 0.61 1.17 to 0.04 .04
Information processing speeda
Model 1 1.37 2.56 to 5.30 .50
Model 2 1.29 4.98 to 2.40 .49
Model 3 1.38 5.15 to 2.40 .47
Model 4 1.37 5.30 to 2.56 .49
Immediate word recalla
Model 1 0.15 4.33 to 4.03 .95
Model 2 2.63 6.40 to 1.15 .17
Model 3 3.39 7.23 to 0.45 .08
Model 4 3.45 7.45 to 0.55 .09
Delayed word recalla
Model 1 0.44 1.71 to 0.82 .49
Model 2 1.00 2.18 to 0.18 .10
Model 3 1.05 2.25 to 0.14 .09
Model 4 1.02 2.26 to 0.23 .11
Response inhibitionb
Model 1 0.01 0.09 to 0.06 .74
Model 2 0.04 0.04 to 0.11 .33
Model 3 0.03 0.04 to 0.10 .44
Model 4 0.02 0.06 to 0.10 .65
Model 1: Adjustment for age. Model 2: Model 1  adjustments for sex, diabetes, and educational level. Model 3: Model 2  adjustments for
smoking, alcohol consumption, waist circumference, total cholesterol/HDL cholesterol ratio, triglycerides, and lipid-lowering medication use. Model
4: Model 3  adjustments for systolic blood pressure, cardiovascular disease, depression, and eGFR.
a Higher scores indicate better performance (MMSE score for global cognitive functioning, number of digits for information processing speed,
number of words for total and delayed word recall) .
b Lower scores indicate better performance. Scores for pentosidine and response inhibition (seconds) are log-transformed
c A regression coefficient of 0.14 indicates that one unit increase in log-transformed pentosidine level is associated with a decrease of 0.14
points on a test for global cognitive functioning.
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fore, in our study the association between SAF and mem-
ory was most robust. Because not all AGEs may end up in
the circulation (13, 14), our results indicate that SAF may
be a better marker for AGE accumulation in brain tissue
than plasma AGEs.
The associations between SAF or plasma pentosidine
and cognitive performance were not significantly different
between individuals with and without type 2 diabetes.
Although our study may not have enough power to detect
significant differences, our results are in line with previous
research demonstrating no interaction between diabetes
and urinary pentosidine on cognitive decline (15).
Accumulation of AGEs in the brain has been linked to
AD by increasing inflammation, oxidative stress, and sub-
sequent neuronal dysfunction (6). These mechanisms may
be involved in the development of cognitive impairment.
Interestingly, in our study the strongest association was
found between SAF and delayed word recall, which is the
best neuropsychological predictor of AD (29). However,
associations of SAF with cognitive functions were atten-
uated after adjustment for potential confounders/media-
tors. Several (cardio)vascular risk factors may confound
the relationship between AGEs and cognitive impairment.
Diabetes has been associated with higher accumulation
of AGEs (5) and cognitive decline (30). In addition, re-
search has shown that obesity increases the risk of devel-
oping dementia and cognitive impairment, possibly in part
through the accumulation of AGEs (31, 32). In addition,
higher levels of lipids, which are involved in the formation
of AGEs (33), may also increase the risk of cognitive im-
pairment (34). In our sample, however, lipids were not
associated with SAF.
In addition to in vivo production, AGEs have been
found in cigarettes (35), and therefore smoking can in-
crease AGE levels and may increase the risk of cognitive
impairment (36). High alcohol consumption may increase
oxidative stress, and thereby AGE levels (37), and can
affect cognitive function (38). However, in our sample,
high SAF level was not associated with high alcohol
consumption.
Some other factors may mediate the association be-
tween AGEs and cognitive impairment, eg, systolic blood
pressure, depression, kidney functioning, and cardiovas-
cular disease. AGE accumulation may contribute to vas-
cular stiffening, by collagen cross-linking of the vascular
wall and thereby leading to (systolic) hypertension (39),
which has been associated with lower cognitive perfor-
mance and lower total brain matter volume (40). Addi-
tionally, depression has been associated with both vascu-
lar stiffness (41) and cognitive decline (42), but in our
sample, depression was not associated with SAF. Further-
more, the kidney metabolizes and removes plasma AGEs
and is a site for accumulation of AGEs. Research has
shown that a decreased GFR is associated with both higher
plasma AGE levels (43) and more cognitive decline (44). A
decreased GFR may therefore mediate the association be-
tween AGEs and cognitive impairment but may also pre-
dict AGE accumulation. Finally, AGEs can lead to cardio-
vascular disease, through mechanisms discussed previously
(eg, vascular stiffness and hypertension), which can in turn
lead to cognitive impairment (45).
It is important to note that some of the variables we
adjusted for, eg, GFR, systolic blood pressure, and car-
diovascular disease, could be part of the causal pathway
from AGEs to cognitive impairment. Therefore, we may
have overadjusted our associations, resulting in a reduc-
tion in the potential total causal effect of AGEs on cogni-
tion by controlling for an intermediate variable (46).
Moreover, because participants that were excluded from
analyses (due to missing values) had higher SAF levels and
lower cognitive scores, our results may be an underesti-
mation of the true association of AGEs and cognitive
functions.
Furthermore, the associations between AGE accumu-
lation and cognition may be stronger in individuals with
cognitive impairment. Studies that found associations
with plasma AGEs mostly investigated this in individuals
with cognitive impairment or dementia (16, 47). In addi-
tion, in one recent study, SAF was associated with cogni-
tive impairment (score  1.5 SD in any domain from
age-, sex-, and education-adjusted norms) (12). Stronger
associations could emerge in longitudinal data in which
participants develop cognitive decline or impairment (15).
Strengths and limitations
Our study has several strengths. A major strength is that
it is the first study to associate SAF and several plasma
AGEs with separate cognitive domains. In addition, we
were able to adjust for multiple important potential con-
founders. Our study also has some limitations. First, due
to the cross-sectional design we were not able to address
causal relationships. However, longitudinal data are not
available yet. Second, SAF may reflect not only skin AGEs,
but also non-AGE skin fluorophores (11). Nevertheless,
results of previous research support the use of SAF as a
marker for skin tissue AGEs (11). Third, it remains un-
clear whether SAF is an accurate reflectance of the level
of AGE accumulation in the brain. However, research
has shown that higher SAF is associated with lower
brain volume (12).
Conclusion
We found significant inverse associations between SAF,
a potential marker of tissue AGEs, and memory. These
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aastricht user on 16 Septem
ber 2021
were attenuated and became nonsignificant after adjust-
ment for vascular risk factors and depression. In addition,
we found associations of SAF with response inhibition and
of pentosidine with global cognitive functioning, albeit
not robust. Our results may suggest that AGEs are in-
volved in the development of cognitive decline, particu-
larly memory decline, and possibly in part through the
action of vascular risk factors. More longitudinal research
is needed to examine the effect of tissue and plasma AGEs
on decline in separate cognitive domains.
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